# GMAB — AI stock forecast & analysis

> AI-generated analysis by K3vl4r — 2026-08-13. Informational only, not financial advice.

**Recommendation:** ACCUMULATE

**Scores (0–100):** Overall 7.2 · Fundamentals 7.5 · Technicals 7.3 · Growth 8.5 · Risk 6.5

## Summary

Genmab's recent EU approval of TEPKINLY and positive Phase 3 EPCORE DLBCL-4 results provide catalysts for revenue acceleration, but high debt levels and valuation sensitivity to near-term catalysts create risk. The stock is trading above the base target with strong momentum from earnings-driven optimism, though technical resistance at $31.186 may cap short-term upside.

## Price targets (6-month horizon)

- Bear: $28.06
- Base: $32.71
- Bull: $37.02

## News context

Recent earnings call highlights strong revenue growth (25% YoY) and raised full-year guidance to $4.3B–$4.5B due to non-DARZALEX products. Guggenheim raised its price target to $42, but the stock is currently trading above the base target ($31.50). The market appears pricing in near-term catalysts rather than GAAP profitability, with high sensitivity to clinical data readouts.

## About
- Methodology: https://app.k3vl4r.com/methodology
- Full report: https://app.k3vl4r.com/r/gmab-ai-stock-forecast-aac4740a27240adcea6ed1bdf18c36fc
- AI-generated; model outputs can be wrong. Not financial advice.